Bellicum Pharmaceuticals Prices Initial Public Offering of 7,350,000 Shares of Common Stock
18 December 2014 - 11:00PM
Business Wire
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company
focused on discovering and developing novel cellular
immunotherapies, today announced the pricing of its initial public
offering of 7,350,000 shares of its common stock, an increase of
1,100,000 shares from the number of shares originally offered, at a
public offering price of $19.00 per share. All of the shares of
common stock are being offered by Bellicum. The Company's common
stock has been approved for listing on the NASDAQ Global Market and
is expected to begin trading today (December 18, 2014) under the
ticker symbol "BLCM." In addition, Bellicum has granted the
underwriters a 30-day option to purchase up to an additional
1,102,500 shares of common stock at the offering price.
Jefferies LLC, Citigroup Global Markets Inc. and Piper Jaffray
& Co. are acting as joint book running managers for the
offering and Trout Capital LLC is acting as co-manager for the
offering.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
December 17, 2014. This offering will be made only by means of a
prospectus, copies of which may be obtained from Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by telephone at (877)
547-6340, or by e-mail at Prospectus_Department@Jefferies.com;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, by email at
prospectus@citi.com, or by telephone at 1-800-831-9146; or Piper
Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402, or by telephone at
800-747-3924 or by e-mail at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused
on discovering and developing novel cellular immunotherapies for
various forms of cancer, including hematological cancers and solid
tumors, as well as orphan inherited blood disorders. The Company is
using its proprietary Chemical Induction of Dimerization, or CID,
technology platform to engineer and control components of the
immune system in real time. The Company is developing
next-generation product candidates in some of the most important
areas of cellular immunotherapy, including hematopoietic stem cell
transplantation, or HSCT, CAR T cell therapy, and dendritic cell
vaccines.
Bellicum PharmaceuticalsInvestors:Pete Rahmer,
646-378-2973prahmer@troutgroup.comMedia:Brad Miles,
646-513-3125bmiles@bmccommunications.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024